Last reviewed · How we verify
PGL4001, progestin
PGL4001, progestin is a Progestin (progesterone receptor agonist) Small molecule drug developed by PregLem SA. It is currently in Phase 3 development for Heavy menstrual bleeding, Preterm labor prevention. Also known as: Ulipristal acetate.
PGL4001 is a selective progesterone receptor agonist that mimics the action of the natural hormone progesterone to modulate uterine contractility and endometrial function.
PGL4001 is a selective progesterone receptor agonist that mimics the action of the natural hormone progesterone to modulate uterine contractility and endometrial function. Used for Heavy menstrual bleeding, Preterm labor prevention.
At a glance
| Generic name | PGL4001, progestin |
|---|---|
| Also known as | Ulipristal acetate |
| Sponsor | PregLem SA |
| Drug class | Progestin (progesterone receptor agonist) |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
As a progestin, PGL4001 binds to progesterone receptors in the uterus and endometrium, suppressing myometrial contractions and promoting endometrial changes that support pregnancy maintenance or prevent abnormal uterine bleeding. This mechanism allows it to address conditions where progesterone deficiency or receptor dysfunction contributes to pathology, such as heavy menstrual bleeding or preterm labor prevention.
Approved indications
- Heavy menstrual bleeding
- Preterm labor prevention
Common side effects
- Headache
- Abdominal pain
- Nausea
- Breast tenderness
Key clinical trials
- PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PHASE3)
- PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PGL4001, progestin CI brief — competitive landscape report
- PGL4001, progestin updates RSS · CI watch RSS
- PregLem SA portfolio CI
Frequently asked questions about PGL4001, progestin
What is PGL4001, progestin?
How does PGL4001, progestin work?
What is PGL4001, progestin used for?
Who makes PGL4001, progestin?
Is PGL4001, progestin also known as anything else?
What drug class is PGL4001, progestin in?
What development phase is PGL4001, progestin in?
What are the side effects of PGL4001, progestin?
What does PGL4001, progestin target?
Related
- Drug class: All Progestin (progesterone receptor agonist) drugs
- Target: All drugs targeting Progesterone receptor (PR)
- Manufacturer: PregLem SA — full pipeline
- Therapeutic area: All drugs in Gynecology / Women's Health
- Indication: Drugs for Heavy menstrual bleeding
- Indication: Drugs for Preterm labor prevention
- Also known as: Ulipristal acetate
- Compare: PGL4001, progestin vs similar drugs
- Pricing: PGL4001, progestin cost, discount & access